Text Space Image
Search

Nuclear Medicine

          The Department of Nuclear Medicine at Safdarjung hospital is one of the oldest in the country. 

           Nuclear Medicine Department is the only hospital under Central Health Services to have this advanced facility in Delhi NCR after AIIMS, New Delhi.. It offers state-of-the-art diagnostic facilities to indoor patients and outdoor patients.

 

  1. PET-CT 
  2. Dual Head Gamma Camera (SPECT-CT)
  3. Thyroid Uuptake Probe with Well Counter 

 

     Both general public and the beneficiaries of the Central Government Health Services are extended this benefit.

 

The department is located in the Zone-1, Basement -1, SSB Block and Ground Floor and also in H- Block of VMMC & Safdarjung Hospital.

 

Working Hours:

9:00AM to 4:00 PM with a lunch break (Monday to Friday)

9:00 AM to 1:00 PM (Saturdays)

Closed on all gazetted holidays and Sundays

 

Registration Time:

9:00 AM to 11:30 AM (Monday to Friday)

9:00 AM to 11:00 AM (Saturdays)

Or if any special instructions

Safarjung Hospital & Nuclear Medicine in India

            First department of Nuclear Medicine in India was established at Safdarjung Hospital 50 years ago. After AIIMS, New Delhi, VMMC and Safdarjung Hospital is the only hospital under Central health services to have this advanced facility in Delhi NCR.

 

Nuclear Medicine:  

            Nuclear medicine is a branch of medicine that uses small amounts of radioactive material (unsealed sources of radiation) to diagnose or treat a variety of diseases, including many types of cancers, heart disease and certain other abnormalities within the body. Organ /tissue specific compounds, known as radiopharmaceuticals, are administered to the patient for diagnostic and therapeutic procedures. Nuclear medicine imaging and non-imaging procedures provide important information about functional status of the body organs. Nuclear medicine or radionuclide imaging procedures are noninvasive and usually painless medical tests that help physicians diagnose medical conditions. 

Radiopharmaceuticals are administered to the patient for diagnostic and therapeutic procedures. Nuclear medicine imaging and non-imaging procedures provide important information about functional status of the body organs. 

            Radiotracer technology has made it possible to define disease in terms of physiology and biochemistry rather than anatomy or histopathology. Whereas Ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI) define disease on the basis of abnormal structure, Positron Emission Tomography (PET) and Single Photon Emission Tomography (SPECT) imaging permits 3D reconstruction of data, increasing the sensitivity and anatomical localization of lesions in the skeleton, brain and heart. The sensitivity of localization of tumors is also increased. In Nuclear Medicine the emphasis is on function and chemistry rather than structure. 

            Radionuclides are also used for therapy of malignant and non-malignant conditions. A lot of progress has taken place over the past few years in Therapeutic Nuclear Medicine. With the use of suitable radiopharmaceuticals targeted therapy is also possible.  Nuclear medicine uses small amounts of radioactive material to diagnose or treat a variety of diseases, including many types of cancers, heart disease and certain other abnormalities within the body.

 

Non-Imaging procedures e.g. Thyroid Uptake Tests are also being done.

At present there is no content available for this section, once content will be available would be updated.

 

 

  1. BRIEF ABOUT PET-CT

A new state-of-the-art PET-CT system (Siemens Biograph mCT 64-slice) worth ₹20.6,00,00,00 Cr.has been installed in the SSB block department of Nuclear Medicine. 

PET-CT has become an essential tool in the diagnosis, prognosis, treatment planning, and follow-up of cancer patients. Following PET-CT Scans are being carried out in the Department.

  • FDG PET-CT scan for various Oncological and non-oncological cases

    • FDG PET-CT Myocardial Viability Scan

    • FDG PET-CT Brain scan

    • Ga-PSMA Scan for Prostate Cancer

    • Ga-DOTANOC scan for Neuroendocrine Tumor  

    • 68Ga- Exendin scan for Insulinoma 

    • 68Ga-FAPI Scan

It has particular clinical relevance in the management of:

  • Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma

  • Lung cancer, Neuroendocrine Tumors (NETs), and Prostate cancer

  • Advanced PET imaging studies including FDG-PET, DOTANOC, FAPI, PSMA, and other specialized scans.

  • Myocardial Viability

The facility also supports multiple clinical departments, including Medical Oncology, Radiation Oncology, Hematology, Urology, Nephrology, and Pediatric Oncology.

PET-CT imaging is essential prior to the administration of radionuclide therapies such as Lu-PSMA and Lu-DOTANOC for cancer patients, ensuring accurate patient selection and optimal treatment planning.

Beyond oncology, PET-CT also plays an important role in the evaluation of complex and difficult-to-diagnose conditions in cardiology and neurology, further strengthening the hospital’s comprehensive patient care services.

 

  1.   BRIEF ABOUT DUAL HEAD GAMMA CAMERA (SPECT-CT)

A new state-of-the-art Dual head Gamma Camera ( AnyScan SPECT-CT System with 16 slice CT Scan) worth ₹7.89 Cr. has been installed in the SSB Block, Department of Nuclear Medicine. After AIIMS, New Delhi, VMMC and Safdarjung Hospital is the only hospital under Central health services to have this advanced facility in Delhi NCR.

SPECT-CT has become an essential tool in the diagnosis of:

  1. Gastrointestinal system

  • HIDA Scan: to diagnose bile leak, extrahepatic biliary atresia, gall bladder ejection fraction.

  • Tc99m Pertechnetate scan: To diagnose ectopic gastric mucosa eg. Meckel’s. 

  • GI Bleed Study: to diagnose the site of intermittent G.I. Bleed.

  • Salivary gland Scintigraphy: to diagnose obstruction to the flow.

  1. Genitourinary system 

  • DTPA Scan: to diagnose the GFR of kidneys especially differential GFR & drainage from the PCS. Level of obstruction in the urinary tract.

  • DMSA Scan: to diagnose renal cortical defect and acute / chronic pyelonephritis. Locate Ectopic kidney.

  • DRCG study: to diagnose vesicoureteric reflux.

  • Testicular scan: to diagnose testicular torsion.

  1. Skeletal System

  • MDP bone scan (whole body): to diagnose skeletal metastasis. 

  • MDP bone scan (three phase): to diagnose osteomylitis and loosening vs infection of prosthesis.

  1. Endocrinology:

  • Thyroid scan: Hot / cold nodule in the thyroid gland.

  • Parathyroid scan: to diagnose parathyroid adenoma and determine its location.

  1. Cardiology: 

  • Myocardial perfusion scan: to diagnose stress induced reversible perfusion defect. Left ventricular wall motion abnormalities.

  • M.U.G.A. scan: it is gold standard test to diagnose Left Ventricular ejection fraction. 

  • V/Q scan: to diagnose pulmonary thromboembolism.

  1. Brain Scan (with Technitium -GHA / ECD / HMPAO): to diagnose abnormalities in cerebral perfusion.

 

 

  1.  NON-IMAGING DIAGNOSTIC FACILITIES:

 

  1. BRIEF ABOUT THYROID UPTAKE PROBE WITH WELL COUNTER

This equipment Thyroid Uptake System with a well counter is used in following cases

  • In patients suffering from thyroid disorders-helping in differentiating         Grave’s disease from various Thyroiditis.

  • In planning 131-Iodine therapy for Grave’s disease patients. 

  • In planning high-dose 131-iodine therapy for Thyroid Cancer patients.

Thyroid uptake probe with well counter is available for in-vivo and in-vitro studies.

  1. THERAPY:

Department has facility to provide radionuclide therapy facility to patients of thyrotoxicosis. Other radionuclide therapy include  bone pain palliation with 32P, 

  • 131-Iodine to patients of thyrotoxicosis. 

    • Department is in advance stage of starting the following therapies: 

  • Lu-PSMA Therapy for Cancer Prostrate 

  • Lu-DOTANOC Therapy for NET 

FUTURE PLAN OF ACTION: 

 

1. The tendering process for procurement of a 2nd PET-CT and 2nd SPECT-CT (Gamma Camera) equipment is currently in progress.

 

2. Establishment of a Nuclear Medicine High-Dose Therapy Isolation Ward for patients

with Thyroid Cancer, Neuroendocrine Tumors (NETs), Prostate Cancer, and other

Oncological conditions is under progress.

Sr. No.NameDesignation
1Dr. Padma A. NamgyalSAG & HOD
2Dr. R. S. SethiProfessor & Consultant
3Dr. Aditi KhuranaCMO (NFSG)
4Dr. Deepa KumarAssociate Professor
5Dr. Tejesh P. SinghAssistant Professor

TECHNICAL Staff:

Ms. Vaishali Vaish                   Radiation Safety Officer

Sh. Surendra Kr. Sharma          Radiation Safety Officer

Mr. Mahesh Kumar                  Radiopharmacist

Ms. Bharti Maurya                   Lab Technician for Radioisotopes

Mr. Mukesh Kumar                  Lab Technician for Radioisotopes

Mr. Satyender Kr. Patel            Lab Technician for Radioisotopes

Mr. Kartik Saroha                     Lab Technician for Radioisotopes

Ms. Thangjam Surjalata            Lab Technician for Radioisotopes

 

                                                    (As on 15.09.2026)

At present there is no content available for this section, once content will be available would be updated.

At present there is no content available for this section, once content will be available would be updated.

SEMINARS AND CONFERENCES

 

1. Participation in the 5th CT Workshop for Nuclear Medicine Physicians at NIMS,

Hyderabad (4–5 April 2025) by Dr. Padma A. Namgyal and Dr. R.S. Sethi, Consultant

& Professor.

 

2. Participated in " A.E.R.B Awareness Programme on Radiation Safety in Nuclear

Medicine Facilities held on 30th May 2025 at Auditorium, Scope Minar, Laxmi Nagar,

New Delhi Dr. Padma A. Namgyal, SAG & Head, Ms. Vaishali Vaish, RSO, Lab Tech.

(Radioisotope), Mr. Surendra Kumar Sharma, RSO, Mr Mahesh Kumar,

Radiopharmacist, Ms. Bharti Maurya and Mr. Mukesh Kumar, Lab Technician

(Radioisotope.

 

3. Completion of Mini Fellowship in Nuclear Medicine and PET-CT at Apollo Radiology

International Academy (3 May 2025 – 14 June 2025) by Dr Padma A Namgyal, SAG

& Head and Dr. R.S. Sethi, Consultant & Professor.

 

4. Participation in the 23rd Annual Conference of Association of Nuclear Medicine

Physicians of India at AIG Hospitals, Hyderabad (29–31 August 2025) by by Dr

Padma A Namgyal, SAG & Head.

 

5. Pariticapation in BCME Course held in V.M.M.C & Safdarjung Hospital from 2nd -4th   Sept 2025 by Dr. Deepa Kumar, Associate Professor and Dr. Tejesh Pratap Singh,

Assisstant Professor.

 

 

6. Participation in CME Update in Prostate Cancer: Focus on Theranostics at ACTREC,

Tata Memorial Centre, Mumbai (1–2 November 2025) by by Dr Padma A Namgyal,

SAG & Head and Dr. R.S. Sethi, Consultant & Professor, Nuclear Medicine.

 

7. Participation in the 17th Asia Oceania Congress of Nuclear Medicine and Biology and

57th Annual Conference of Society of Nuclear Medicine India held at Chennai (4–7

December 2025) by by Dr Padma A Namgyal, SAG & Head, Dr. R.S Sethi,

Consultant & Professor, Dr Aditi Khurana, CMO (NFSG), Dr. Deepa Kumar,

Associate Professor, Nuclear Medicine.

 

8. Participation in Contact Programme in Hospital Management (16–20 February 2026) by Dr. Deepa Kumar, Associate Professor.

 

 

9.  Participation in 9th NAMPICON 2026 at Tata Memorial Hospital, Mumbai (28–29

March 2026) by Mr. Surendra Kumar Sharma, RSO, Ms. Bharti Maurya and Mr.

Mukesh Kumar, Lab Technician (Radioisotope).

ACADEMIC ACTIVITIES

 

1.  Young Medical Faculty Ph.D. Programme 2025 under DHR-ICMR by Dr. Deepa

Kumar, Associate Professor,on: “Pre-treatment FDG PET/CT Radiomics and

Metabolic Features for EGFR Mutation Detection and Treatment Response Assessment to Tyrosine Kinase Inhibitor Therapy in Non-Small Cell Lung Cancer Patients.”

 

 

3. Successful initiation of the Ph.D. Programme in Nuclear Medicine affiliated under

GGSIPU, New Delhi.

 

4. DNB Programme in Nuclear Medicine is in the final stages of approval and

Implementation.

TEACHING ACTIVITIES

  • Regular academic meetings, journal clubs, Teaching and training of residents.

    • Teaching DNB students of Endocrinology Dept.

      • Teaching and training of B.Sc. MIT students of Radiology Dept.

 

TRAINING AND WORKSHOPS

1. Training in Nuclear Medicine at AIIMS, New Delhi (19 January 2026 – 19 February

2026) attended by Dr. R.S. Sethi, Consultant & Professor, Nuclear Medicine.

 

2. Training in Nuclear Medicine at ACTREC, Tata Memorial Centre, Navi Mumbai (2

March 2026 – 14 March 2026) attended by Dr. R.S. Sethi, Consultant & Professor,

Nuclear Medicine.

 

3. Short-term Observership/Training in PET-CT guided interventions at PGIMER,

Chandigarh (06 April 2026 – 11 April 2026) attended by Dr. R.S. Sethi, Consultant &

Professor, Nuclear Medicine.

 

4. Training on BMW Rules and Management at Safdarjung Hospital conducted by Dr

Aditi Khurana, CMO (NFSG).

 

5. Participation in Kayakalp Manthan Workshop held on 29 January 2026 by Dr Aditi

Khurana, CMO (NFSG).

 

6. Short-term Observership/Training in the Department of Nuclear Medicine, AIIMS,

New Delhi by Short-term Observership/Training by Ms. Vaishali Vaish, RSO, Mr.

Surendra Kumar Sharma, RSO, Mr Mahesh Kumar, Radiopharmacist, Ms. Bharti

Maurya and Mr. Mukesh Kumar, Lab Tech. (Radioisotope).

At present there is no content available for this section, once content will be available would be updated.

At present there is no content available for this section, once content will be available would be updated.